Cyclosporine

At a glance

Overview

Cyclosporine transformed transplantation by allowing more effective suppression of immune rejection. Systemic products are also approved for selected severe rheumatoid arthritis and psoriasis settings, while separate ophthalmic products address specific eye conditions. The formulations are not interchangeable merely because they contain the same active molecule. Neoral is a modified microemulsion formulation with different absorption from nonmodified Sandimmune. The clinical objective is deliberate immune suppression in a defined disease, not general immune enhancement. Because the concentration needed for benefit can also cause toxicity, treatment depends on the indication, concomitant medicines, organ function, and careful interpretation of drug concentrations where appropriate.

Supporting sources [1] [2]

How it works

Cyclosporine binds intracellular cyclophilin. The resulting complex inhibits calcineurin, reducing activation of transcription factors required for interleukin-2 production and T-cell activation. This limits cell-mediated immune responses, including graft rejection. The pathway explains both efficacy and increased susceptibility to infection, while renal vascular and other effects contribute to toxicity. Local ophthalmic exposure and systemic exposure have different clinical safety contexts.

Supporting sources [1] [2]

Established systemic roles

Neoral labeling covers prevention of rejection in selected organ transplants and specified rheumatoid arthritis and psoriasis populations. Choice of therapy depends on disease severity and previous treatment. Systemic immunosuppression may be combined with other agents, but combined effects on infection risk and toxicity must be considered explicitly.

Supporting sources [1]

A major advance in transplantation

An early randomized kidney-transplant study found better graft survival with a cyclosporine-based regimen than with the then-standard azathioprine regimen, alongside higher creatinine measurements. The study illustrates both the drug’s clinical impact and its renal tradeoff. Modern protocols have evolved, so historical comparators should not be presented as today’s universal standard.

Supporting sources [2]

Important harms and interactions

Systemic treatment can cause nephrotoxicity and hypertension and increase infection and malignancy risks. CYP3A-related interactions and other nephrotoxic drugs can substantially alter risk. Tremor, gum enlargement, and excess hair growth are additional recognized effects. Monitoring must distinguish drug toxicity from the underlying disease or, after transplantation, rejection.

Supporting sources [1]

Can Neoral and Sandimmune simply be swapped?

The label warns against unsupervised substitution because absorption and exposure differ. A brand or formulation change may require close review and concentration monitoring. The existence of separately formulated eye products likewise does not mean that oral cyclosporine can be used in the eye or that systemic warnings apply identically to local exposure.

Supporting sources [1]